1
2
3
4

최신정보

  • 2022.03.25

    2022_Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug Responses

    Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug ResponsesAbstractIntratumor heterogeneity (ITH) stands as one of the main difficulties in the treatment of colorectal cancer (CRC) as it causes the development of resistant clones and leads to heterogeneous drug responses. Here, 12 sets of patient-derived organoids (PDOs) and cell lines (PDCs) isolated from multiple regions of single tumors from 12 patients, capturing ITH by multiregion sampling of individual tumors, are presented. Whole-exome sequencing and RNA sequencing of the 12 sets are performed. The PDOs and PDCs of the 12 sets are also analyzed with a clinically relevant 24-compound library to assess their drug responses. The results reveal unexpectedly widespread subregional heterogeneity among PDOs and PDCs isolated from a single tumor, which is manifested by genetic and transcript-x-xional heterogeneity and strong variance in drug responses, while each PDO still recapitulates the major histologic, genomic, and transcript-x-xomic characteristics of the primary tumor. The data suggest an imminent drawback of single biopsy-originated PDO-based clinical diagnosis in evaluating CRC patient responses. Instead, the results indicate the importance of targeting common somatic driver mutations positioned in the trunk of all tumor subregional clones in parallel with a comprehensive understanding of the molecular ITH of each tumor.

    자세히 보기

  • 2022.03.25

    2021_Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies

    Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration BiopsiesThree-dimensional cultures of human pancreatic cancer tissue also known as "organoids" have largely been developed from surgical specimens. Given that most patients present with locally advanced and/or metastatic disease, such organoids are not representative of the majority of patients. Therefore, we used endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) to collect pancreatic cancer tissues from patients with advanced pancreatic cancer to create organoids, and evaluated their utility in pancreatic cancer research.

    자세히 보기

  • 2022.03.25

    2020_Establishment and characterization of 18 human colorectal cancer cell lines

    Establishment and characterization of 18 human colorectal cancer cell lines

    자세히 보기

공지사항

  • 2023.05.11

    ** 2023년 5,6월 분양 일정 안내 **

    ** 2023년 5,6월 분양 일정 안내 **5월 29일 월요일 (부처님오신날 대체공휴일) 휴일로월요일 '택배분양'이 진행되지 않으며5월 30일 화요일에 발송됩니다.또한, 6월 5일 월요일 택배분양은 6일 (현충일) 휴일로택배 발송이 불가하여 분양이 진행되지 않습니다.또한 전산 휴무로 6월 5일 당일은유선연결 및 상담업무가 진행되지 않습니다.6월 7일 수요일 직접분양은 정상 진행됩니다.이점 고려하여 분양 신청을 진행해주시고불편하신 사항은 한국세포주은행 카카오채널 및 메일(kclb@kclb.kr)로 문의주시면 감사하겠습니다.

    자세히 보기

  • 2022.07.21

    거래명세서와 견적서의 '공급받는자' 정보부분

    거래명세서와 견적서의 '공급받는자' 정보부분은마이페이지-회원정보수정에서, 사업자정보란에 발급 원하시는 기관의 정보를 입력해 주셔야합니다.'정보가 없을경우' 공란으로 나오며, 마이페이지에서 수정하시면 정보가 입력됩니다. 참고하여 주시면 감사하겠습니다.

    자세히 보기

  • 2022.03.07

    ** 3D 오가노이드를 활용한 HTS(High Throughput Screening) 서비스 안내 **

    ** 3D 오가노이드를 활용한 HTS(High Throughput Screening) 서비스 안내 **   한국세포주은행에서는 3D 오가노이드를 활용한 high throughput drug screening service를 지원합니다.  2D 세포주 및 3D 오가노이드에 대한 drug screening 비교 service도 가능합니다.    오가노이드를 활용한 drug screening service에 대한  자세한 내용은 이메일(kclb@kclb.kr)이나 카카오채널로 문의하여 주시면  자세한 절차 안내해드리겠습니다.    감사합니다.

    자세히 보기

Korean Cell Line Bank, Korean Cell Line Research Foundation,
101, Daehak-ro, Jongno-gu, Seoul, 03080, Korea
대표자 : 박재갑 | 개인정보보안책임자 : 신영경 | 사업자 등록번호 : 208-82-03887
통신판매업 신고 제2015-서울혜화-0125호 | Tel : 82-2-3668-7915 | Fax : 82-2-742-0021 | Email : kclb@kclb.kr

KCLB (C) is a registered mark of Korean Cell Line Bank. All rights reserved. 1998~2015